Loss of PTEN promotes tumor development in malignant melanoma

Cancer Research

Volumn 63, Issue 11, 2003, Pages 2881-2890

  Stahl, Jill M ^a   Cheung, Mitchell ^a   Sharma, Arati ^a   Trivedi, Nishit R ^a   Shanmugam, Sumathi ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CHROMOSOME 10; ENZYME ACTIVATION; GENE IDENTIFICATION; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 10; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0038243115     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Schalick, W. O., Albino, A. P., Reed, J. A., Fountain, J. W., Scott, G. A., SuPont, G., Puri, N., Herlyn, M., Halpern, A. C., Gallager, R. P., Ho, V. C., Grin, C. M., Sagabiel, R., Barnhill, R. L., Elder, D. E., Montone, K. T., Neades, G. T., Bernstein, S. C., Roenigk, R. K., Kim, S. H., Harwood, A. R., Agarwala, S. S., Kim, S. H., Kirkwood, J., Sharfman, W. H., Sznol, M., Abrams, J., and Parkinson, D. Cutaneous Oncology, pp. 180-348. Malden, MA: Blackwell Science, Inc., 1998.
2. Thompson, F. H., Emerson, J., Olson, S., Weinstein, R., Leavitt, S. A., Leong, S. P., Emerson, S., Trent, J. M., Nelson, M. A., Salmon, S. E., and et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet. Cytogenet., 83: 93-104, 1995.
3. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S. r., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash. DC), 264: 436-440, 1994.
4. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
5. Lee, W. H., Bookstein, R., Hong, F., Young, L. J., Shew, J. Y., and Lee, E. Y. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science (Wash. DC), 235: 1394-1399, 1987.
6. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Wash. DC), 275: 1943-1947, 1997.
7. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V. Identification of a candidate tumour suppressor gene. MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.
8. Li, D. M., and Sun, H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res., 57: 2124-2129, 1997.
9. Newton, J. A. Genetics of melanoma. Br. Med. Bull., 50: 677-687, 1994.
10. Bastian, B. C., LeBoit, P. E., Hamm, H., Brocker, E. B., and Pinkel, D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res., 58: 2170-2175, 1998.
11. Robertson, G. P., Herbst, R. A., Nagane, M., Huang, H. J., and Cavenee, W. K. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res., 59: 3596-3601, 1999.
12. Healy, E., Belgaid, C., Takata, M., Harrison, D., Zhu, N. W., Burd, D. A., Rigby, H. S., Matthews, J. N., and Rees, J. L. Prognostic significance of allelic losses in primary melanoma. Oncogene, 16: 2213-2218, 1998.
13. Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F., and Zeuthen, J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res., 57: 3660-3663, 1997.
14. Teng, D. H., Hu, R., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., Vinson, V. L., Gumpper, K. L., Ellis, L., El-Naggar, A., Frazier, M., Jasser, S., Langford, L. A., Lee, J., Mills, G. B., Pershouse, M. A., Pollack, R. E., Tomos, C., Troncoso, P., Yung, W. K., Fujii, G., Berson, A., and Steck, P. A. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res., 57: 5221-5225, 1997.
15. Marsh, D. J., Coulon, V., Lunetta, K. L., Rocca-Serra, P., Dahia, P. L., Zheng, Z., Liaw, D., Caron, S., Duboue, B., Lin, A. Y., Richardson, A. L., Bonnetblanc, J. M., Bressieux, J. M., Cabarrot-Moreau, A., Chompret, A., Demange, L., Eeles, R. A., Yahanda, A. M., Fearon, E. R., Fricker, J. P., Gorlin, R. J., Hodgson, S. V., Huson, S., Lacombe, D., Eng, C., and et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet., 7: 507-515, 1998.
16. Tsao, H., Zhang, X., Benoit, E., and Haluska, F. G. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene, 16: 3397-3402, 1998.
17. Boni, R., Vortmeyer, A. O., Burg, G., Hofbauer, G., and Zhuang, Z. The PTEN tumour suppressor gene and malignant melanoma. Melanoma Res., 8: 300-302, 1998.
18. Herbst, R. A., Podewski, E. K., Mommert, S., Kapp, A., and Weiss, J. PTEN and MXI1 allelic loss on chromosome 10q is rare in melanoma in vivo. Arch. Dermatol. Res., 291: 567-569, 1999.
19. Birck, A., Ahrenkiel, V., Zeuthen, J., Hou-Jensen, K., and Guldberg, P. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J. Investig. Dermatol., 114: 277-280, 2000.
20. Reifenberger, J., Wolter, M., Bostrom, J., Buschges, R., Schulte, K. W., Megahed, M., Ruzicka, T., and Reifenberger, G. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch., 436: 487-493, 2000.
21. Naus, N. C., Zuidervaart, W., Rayman, N., Slater, R., van Drunen, E., Ksander, B., Luyten, G. P., and Klein, A. Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int. J. Cancer, 87: 151-153, 2000.
22. Celebi, J. T., Shendrik, I., Silvers, D. N., and Peacocke, M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet., 37: 653-657, 2000.
23. Robertson, G. P., Furnari, F. B., Miele, M. E., Glendening, M. J., Welch, D. R., Fountain, J. W., Lugo, T. G., Huang, H. J., and Cavenee, W. K. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl. Acad. Sci. USA, 95: 9418-9423, 1998.
24. Hwang, P. H., Yi, H. K., Kim, D. S., Nam, S. Y., Kim, J. S., and Lee, D. Y. Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett., 172: 83-91, 2001.
25. Simpson, L., and Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res., 264: 29-41, 2001.
26. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (Wash. DC), 275: 661-665, 1997.
27. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (Lond.), 385: 544-548, 1997.
28. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., and Hay, N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev., 11: 701-713, 1997.
29. Kulik, G., Klippel, A., and Weber, M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17: 1595-1606, 1997.
30. Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R., and Franke, T. F. Interleukin 3-dependent survival by the Akt protein kinase. Proc. Natl. Acad. Sci. USA, 94: 11345-11350, 1997.
31. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
32. Cheney, I. W., Johnson, D. E., Vaillancourt, M. T., Avanzini, J., Morimoto, A., Demers, G. W., Wills, K. N., Shabram, P. W., Bolen, J. B., Tavtigian, S. V., and Bookstein, R. Suppression of tumorigenicity of glioblastoma cells by adenovirusmediated MMAC1/PTEN gene transfer. Cancer Res., 58: 2331-2334, 1998.
33. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet., 19: 348-355, 1998.
34. Robertson, G. P., Huang, H-J. S., and Cavenee, W. K. Identification and validation of tumor suppressor genes. Mol. Cell. Biol. Res. Comm., 2: 1-10, 1999.
35. Robertson, G. P., Huang, H-J. S., and Cavenee, W. C. Loss of heterozygosity (LOH). In: T. E. Creighton (ed.), Encyclopedia of Molecular Medicine, Vol. 5, pp. 1959-1961. New York: Wiley, 2001.
36. Whang, Y. E., Wu, X, Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., and Sawyers, C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA, 95: 5246-5250, 1998.
37. Dahia, P. L., Aguiar, R. C., Alberta, J., Kum, J. B., Caron, S., Sill, H., Marsh, D. J., Ritz, J., Freedman, A., Stiles, C., and Eng, C. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum. Mol. Genet., 8: 185-193, 1999.
38. Salvesen, H. B., MacDonald, N., Ryan, A., Jacobs, I. J., Lynch, E. D., Akslen, L. A., and Das, S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer, 91: 22-26, 2001.
39. Whiteman, D. C., Zhou, X. P., Cummings, M. C., Pavey, S., Hayward, N. K., and Eng, C. Nuclear PTEN expression and clinicopathologic features in a populationbased series of primary cutaneous melanoma. Int. J. Cancer, 99: 63-67, 2002.
40. Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., and Ittmann, M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA. 98: 11563-11568, 2001.
41. Zhou, X. P., Gimm, O., Hampel, H., Niemann, T., Walker, M. J., and Eng, C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol., 157: 1123-1128, 2000.
42. Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA, 68: 820-823, 1971.
43. Cavenee, W. K., Dryja, T. P., Phillips, R. A., Benedict, W. F., Godbout, R., Gallie, B. L., Murphree, A. L., Strong, L. C., and White, R. L. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature (Lond.), 305: 779-784, 1983.
44. Cavenee, W. K., Hansen, M. F., Nordenskjold, M., Kock, E., Maumenee, I., Squire, J. A., Phillips, R. A., and Gallie, B. L. Genetic origin of mutations predisposing to retinoblastoma. Science (Wash. DC), 228: 501-503, 1985.
45. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
46. Robertson, G. P., Coleman, A. B., and Lugo, T. G. Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6. Cancer Res., 56: 1635-1641, 1996.
47. Wang, S. I., Puc, J., Li, J., Bruce, J. N., Cairns, P., Sidransky, D., and Parsons, R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res., 57: 4183-4186, 1997.
48. Yao, R., and Cooper, G. M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science (Wash. DC), 267: 2003-2006, 1995.
49. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem., 269: 5241-5248, 1994.
50. Kaufmann, S. H., and Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res., 256: 42-49, 2000.
51. Furnari, F. B., Lin, H., Huang, H. J-S., and Cavenee, W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA, 94: 12479-12484, 1997.
52. Reed, J. C. Apoptosis-based therapies. Nat. Rev. Drug Discov., 1: 111-121, 2002.
53. Stewart, A. L., Mhashilkar, A. M., Yang, X. H., Ekmekcioglu, S., Saito, Y., Sieger, K., Schrock, R., Onishi, E., Swanson, X., Mumm, J. B., Zumstein, L., Watson, G. J., Snary, D., Roth, J. A., Grimm, E. A., Ramesh, R., and Chada, S. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol. Med., 8: 451-461, 2002.